You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.
Bloomington, Ind. — The Grant Street Inn has opened a new 16-room addition. The new building was designed and constructed to meet Leadership in Energy and Environmental Design (LEED) certification requirements. The facility will be the fourth LEED-certified building in Bloomington, and the first privately owned LEED-certified building in town. Certification, which is based on energy usage, sustainability and indoor air quality, will be completed upon review of energy and water consumption.
The Grant Street Inn’s new addition was built to match the 1890s style of the original inn. It is a part of CFC’s larger effort toward sustainable living. The addition includes green elements such as energy-saving light fixtures, low-flow showers, solar panel water heaters and a system to capture rainwater and use it to irrigate the lawn and solar panel water heaters.
“Guests can enjoy the usual comforts of our bed and breakfast as we work to reduce our carbon footprint.”
“We are so excited about this addition to the Grant Street Inn,” said Jim Murphy, president of CFC Properties. “Guests can enjoy the usual comforts of our bed and breakfast as we work to reduce our carbon footprint.”
This summer, guests of the inn were given gift cards to the local farmer’s market and encouraged to bring a plant back to the inn to be planted in the guest garden. The items they brought back were incorporated into the dayâs meals. These efforts, and others designed to get people thinking about things they can do to help the environment, will continue.
About CFC Properties
For more than 35 years, CFC Properties has been a leader in the historic restoration, promotion and revitalization of downtown Bloomington, Indiana. This includes the city’s largest bed and breakfast, the Grant Street Inn. CFC also recently expanded to Canton, Illinois, hometown of former president and CEO of Cook Group, Bill Cook. For more information, visit www.cfcproperties.com. Follow The Grant Street Inn on Twitter and Facebook.
Baesweiler, North Rhine-Westphalia — Cook Medical, a world leader in minimally invasive medical technologies, today announced a major development in the extension of its European operations with the opening of a new €15m distribution center in Baesweiler, Germany.
Located less than one hour from Cologne, the new center will be the company’s delivery hub for all European countries providing easy access to Europe’s largest freight airport Cologne/Bonn, as well as to major road and rail networks.
Cook’s increased presence in Germany marks an important step in safeguarding continuity of patient care. The center will streamline Cook’s distribution activity across Europe offering the highest standard, both in terms of device quality and customer service.
“Baesweiler is an ideal location for our European distribution center as we continue to increase our commitment to supporting patients worldwide,” said Bill Doherty, VP EMEA Cook Medical. “Due to its excellent infrastructure and proximity to the cities of Cologne, Dusseldorf and Aachen, it is one of the most efficient logistics locations in Europe – providing our business and patients with increased assurance. This is an important step in achieving our aim to enhance patient care, both with our medical solutions and our streamlined distribution network.”
The distribution center, which has a total storage surface of 5850m2, will stock up to 800,000 products previously stored at Cook Ireland, based in Limerick and William Cook Europe in Denmark. At any one time there will be close to 5,000 different products in stock with 1,500 shipments daily, and up to 20 larger bulk shipments to various distribution partners. In a full year, Cook Medical expects to distribute over half a million packages from the center and will ship regularly to over 100 countries worldwide. The new European Distribution Center joins a network of continental distribution centers serving Cook Medical, with the others being Bloomington, Indiana for the Americas and Shanghai for Asia/Pacific.
The new center will also support Cook in bringing devices to customers in a more environmentally friendly way, with the Baesweiler facility classed as 18.8% more energy efficient than requirements set out in the German Energy Saving Standards. Built with high-quality materials, the structure will be one of Cook’s most energy efficient with solar panels and state of the art insulation ensuring energy efficient heating throughout. The Distribution Center processes are paperless while air pillows replace serrated paper in padding for shipments.
The investment has created 60 jobs with employees responsible for receiving, storing, picking and packing, shipping, returning and labelling medical devices. An additional 20 jobs will be created when a second phase sterilization operation is added in 2014.
The grand opening today will, among other key officials, be attended by Bill Doherty, Mayor of Baesweiler Willi Linkens, and Stephan Jungen of the North Rhine Westphalia development agency. Officials from Cook’s US headquarters also participated in the event.
About Cook Medical
A pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.com. Follow Cook Medical on Twitter and LinkedIn.
Washington, D.C. — Cook Medical, a world leader in minimally invasive medical device technology, has launched its new Otolaryngology/Head and Neck Surgery (OHNS) clinical division to bring the benefits of the company’s devices for non-surgical procedures to a new group of physicians and the patients they treat.
Recognizing the need for specialized minimally invasive devices in otolaryngology, Cook OHNS is researching and developing alternatives to open surgery for treating conditions across several traditional ear, nose and throat (ENT) specialties.
Cook officially unveiled the new clinical division and a selection of its current and upcoming products —salivary duct access tools, stone extractor set, Biodesign® dural advanced tissue graft, Hercules® 3 Stage Wire Guided Balloon and the Chiba EchoTip® Biopsy Needle—at the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) conference in Washington, D.C., this week.
The division’s initial six practice areas of focus are soft tissue repair, salivary gland disease, chronic sinusitis, vocal cord paralysis, obstructive sleep apnea, and interventional airway and esophageal procedures. There is great potential within these six areas to bring new treatment options, many of which are alternatives to open surgery, to millions of patients in the U.S. and globally, Cook officials said.
“We started Cook OHNS to pioneer ways to provide patients with diseases affecting the head and neck with less traumatic alternatives to surgeries. As we met with physicians, we heard loud and clear that they saw many opportunities for minimally invasive medical devices in this field,” said Thomas Cherry, global leader for Cook Medical’s OHNS division. “At our core, we’ve always solved problems for clinicians over Cook’s entire history. So now, Cook OHNS is taking proven interventional tools and techniques and applying them to the emerging science of minimally invasive otolaryngology and head and neck surgery.”
Cook will showcase the following products at AAO-HNS:
Salivary Duct Access Products: Intended to reduce trauma for the patient and reduce the need for open surgery, the tools in this product line help physicians perform minimally invasive sialendoscopy procedures. The devices, which include a wire guide, dilator set, Kolenda introducer sheath and the NGage® and NCircle® salivary stone extractors, help enable physicians to gain access to stones and remove them in the physician’s office without surgery.
Hercules 3 Stage Esophageal Balloon: The Hercules 3 Stage Esophageal Balloon is designed to treat abnormal narrowing of the digestive tract that can interfere with eating, swallowing and digestion. The device is made with proprietary P.E.T. Flex™ technology, a material that optimally combines the high tensile strength and flexibility necessary for a strong balloon that inflates to three distinct and increasing diameters.
Chiba EchoTip Biopsy Needle: The high-visibility EchoTip biopsy needle allows physicians to perform thyroid biopsy with a needle that can be easily seen under ultrasound. High visibility results in more accurate needle placement and reduces the number of needle passes needed to obtain a sufficient sample. The Chiba EchoTip biopsy needle design provides enhanced visualization of needle tip when used with ultrasonic imaging equipment to ensure a strong, hyperechoic reflection and clearly visible images.
“There is a definite need for true out-of-the-box thinking around minimally invasive medical technology for OHNS,” said Patrick Melder, M.D., of ENT Associates of North Georgia and a presenter at the AAO-HNS conference. “Cook Medical has a solid and lengthy track record in innovating minimally invasive technologies, and has the ability to help transform the way we may approach such things as reducing post-tonsillectomy pain or advancing our understanding of the treatment of sinusitis.”
“For months, Thomas Cherry kept saying we could help a large group of patients if we could make our products available to them, and he was right. He was doing what Cook has always done; listened to physicians, heard what they needed and given them the tools to treat patients in a better way,” explained Pete Yonkman, executive vice president of strategic business units for Cook Medical.
OHNS is Cook’s 10th active clinical division. The company currently operates Aortic Intervention, Critical Care, Endoscopy, Interventional Radiology, Lead Management, Peripheral Intervention, Surgery, Urology and Women’s Health divisions as well. Dr. Melder is a paid consultant to Cook Medical with respect to its medical devices.
About Cook Medical
A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving 41 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.com. Follow Cook Medical on Twitter and LinkedIn.
Bloomington, Ind. – With the U.S. Supreme Court ruling upholding the constitutionality of the Affordable Care Act (ACA), Cook Medical now calls for the U.S. Senate to repeal the 2.3 percent medical device excise tax included in that legislation.
“The U.S. House of Representatives has passed, in a bi-partisan vote, legislation to repeal this job-killing tax that puts the health of the American public at risk as companies like Cook have to pay this tax instead of investing in new medical technologies that can save lives,” said Steve Ferguson, chairman of Cook Group. “Now that we know the ACA will not be overturned, the Senate needs to follow the House’s lead and act in the best interests of American patients and American companies who produce these vital medical technologies. Repealing the tax, which is on top line revenues of all companies that sell medical devices in the U.S., is a critical imperative that saves jobs and drives continued medical treatment innovation here at home.”
The threat of the imminent tax has already led companies to move existing manufacturing jobs offshore and plan for future growth outside the U.S., Ferguson added.
“This misguided tax will have a drastic ripple effect on patients, who will be deprived of breakthroughs, research and development, suppliers and local businesses in thousands of communities. We strongly encourage the Senate to repeal the excise tax,” Ferguson said.
About Cook Medical
A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.com. Follow Cook Medical on Twitter and LinkedIn.
Bloomington, Ind. – This is an important week for employees and businesses across Indiana and our nation. The Committee on Ways and Means in the U.S. House of Representatives, with support from both parties, voted 23-11 to approve legislation, H.R. 436 “Protect Medical Innovation Act of 2011,” that would repeal a medical device tax.
The excise tax, which is scheduled to go into effect in January, would harm innovative small-to-midsize medical device companies. It would lead major multinational companies to relocate existing plants and jobs and to build new plants in low-tax nations.
The legislation is scheduled to go the House floor next week, where it is expected to pass. The Senate has not yet taken action on the repeal legislation.
“Today’s action is important to every medical device company, as well as suppliers who offer a multitude of services to companies, whether they mow the lawn, sell cars, provide parts, IT services, create components or otherwise offer commercial support,” said Steve Ferguson, chairman of the board of Cook Group, parent of Cook Medical.
Cook Medical, based in Bloomington, Ind, is the nation’s largest privately owned medical device company and has plants in Indiana, Illinois, North Carolina, California and Pennsylvania.
“This repeal is vital to patients and their caregivers who want their critical-care devices manufactured in the U.S.,” Ferguson said. “The threat of this imminent tax has already led companies to move existing manufacturing offshore and plan for future growth outside the U.S.”
Ferguson was hopeful that more Congress members than the 239 who have supported the repeal will vote to shelve the tax.
“When legislative mistakes are made and policymakers learn more about an issue, the American people expect their leaders to change course based on that new information,” Ferguson said. “We want to thank Rep. Larry Bucshon (IN-8); Rep. Dan Burton (IN-5); Rep. Joe Donnelly (IN-2); Rep. Mike Pence (IN-6); Rep. Todd Rokita (IN-4); Rep. Marlin Stutzman (IN-3); and Rep. Todd Young (IN-9) for being co-sponsors of this important legislation.”
About Cook Medical
A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.com. Follow Cook Medical on Twitter and LinkedIn. Help repeal the device tax by signing a cyber-petition at www.no2point3.com
Bloomington, Ind. — As part of its ongoing commitment to patients needing emerging new cellular therapies, Cook Group has acquired the assets of General BioTechnology LLC and launched a new company, Cook General BioTechnology LLC (CGBT). Based in Indianapolis, CGBT adds valuable new cell and tissue processing and cryopreservation technologies to Cook Group’s existing cellular therapies and manufacturing portfolio that includes Cook MyoSite, Cook Pharmica and Cook Biotech. Details of the acquisition including the cost were not released.
“Our company has been dedicated to advancing the science and practical application of processing and storage of cells and tissues to empower scientific research into new cell-based medical therapies,” said Erik Woods, Ph.D., president of CGBT. “With our team’s deep heritage in cell therapy technologies, CGBT has already been awarded several Small Business Innovation Research grants to improve cryopreservation and biobanking methods. Now as part of Cook Group with all its resources, we look forward to establishing additional partnerships with universities, industry leaders and scientific researchers to help create the future of cell therapies.”
The new company, which has approximately 20 employees, already has contracts with universities to aid in development of advanced cryopreservation and banking procedures for fragile, unique cell and tissue types. Research sponsored by these programs has resulted in the development of several cryopreservation processing patents directly assigned and licensed back to CGBT. Presently, CGBT runs an umbilical cord blood and tissue bank for individual families, The Genesis Bank, and a reproductive tissue bank, Genome Resources.
“Cook Group is positioning our cell therapy portfolio to serve this burgeoning industry, as it is clear that this market is becoming increasingly important to global healthcare advancements,” Neal Fearnot, Ph.D., vice president of Cook Group and chairman of MED Institute, added. “At Cook, we are dedicated to continually innovating and delivering opportunities that advance medical breakthroughs and improve the quality of patient care worldwide, and we see this business acquisition and the launch of CGBT as a major step in that direction.”
About Cook Medical
A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.com. Follow Cook Medical on Twitter and LinkedIn.